Thank you, Mr. Speaker. Mr. Speaker, first of all, the Member has raised this issue about cancer drugs, and I want to give him a specific answer to this. If somebody has cancer and they're receiving treatment in a hospital, those drugs are provided to the person without any means testing or any charge. If after the cancer treatment there is a prescription that is preventative, like tamoxifen for breast cancer, then that is part of the specified condition list, and it would be captured in this new program. So, again, in response to his points, there is -- there is consideration for a drug benefit plan that would cover catastrophic medical costs. For example, the most current treatment for cystic fibrosis is $300,000 per year per client, which is obviously a very huge amount of money for anyone to undertake.

So in terms of the federal government, we don't have any additional information about when pharma care is going to happen. There was a report given to the federal government on the pharma care program prior to the 2019 election, and we delayed the review of the supplementary health benefits program to wait for more information to come forward on pharma care -- national pharma care. It hasn't come forward. So we've decided that we need to move forward with our own review. Thank you.